全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report"

Transcription

1 /wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 : 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天 地 大 厦 A2 座 室 (100080) 摘 要 This report analyzes the worldwide markets for Multiple Sclerosis Therapeutics in US$ Billion. The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through The report profiles 45 companies including Bayer Schering Pharma AG, Biogen Idec Inc., Elan Pharmaceuticals, Inc., Genzyme Corp, Merck Serono SA, Novartis AG, Sanofi-Aventis SA, and Teva Pharmaceuticals Industries Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report. Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

2 目 录 及 图 表 I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study II. EXECUTIVE SUMMARY 1. MARKET HIGHLIGHTS Market Snapshots Market Drivers Market Restraints Major Players 2. MARKET OVERVIEW Increasing Prevalence of Multiple Sclerosis Table 1: World Multiple Sclerosis Prevalence in Thousands by Select Countries for Years 2001 through 2010 (includes corresponding Graph/Chart) Table 2: Prevalence by Types of Multiple Sclerosis (includes corresponding Graph/Chart) MS Therapeutics in the Market Key Multiple Sclerosis Drugs Interferon Drugs Beta Interferon Drugs in Multiple Sclerosis Treatment Non-Interferon Drugs Non-Interferon Drugs in Multiple Sclerosis Treatment High Unmet Need and Rich Pipeline to Expand MS Market Challenges Ahead 3. MARKET TRENDS Interferon-based Drugs Dominate Multiple Sclerosis Market Sales Dip Inevitable for Current Therapies Tough Times Ahead for Betaseron Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies Competitive Landscape Table 3: Global Multiple Sclerosis Market by Leading Drugs (2008 & 2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart) 4. MULTIPLE SCLEROSIS - DRUG PIPELINE Recent Clinical Trial Activity - An Drugs Under Development for Treating Multiple Sclerosis FTY 720 (Fingolimod) Mylinax

3 Laquinimod Alemtuzumab Teriflunomide BG-12 (Oral Fumarate) Rituxan/MabThera (Rituximab) Vaccines for Multiple Sclerosis 5. PRODUCT OVERVIEW Definition Causes of Multiple Sclerosis Different Forms of Multiple Sclerosis Pathology 6. RECENT INDUSTRY ACTIVITY Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat Multiple Sclerosis Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of MS Novartis Obtains FDA Approval for Extavia Merck Serono Collaborates with Brigham and Women's Hospital to Extend Multiple Sclerosis Research Merck Serono Announces Encouraging Phase III Results of Oral Mylinax Merck Serono Acquires Rights to Apitope s Multiple Sclerosis Approach Teva and Active Biotech Obtains Fast Track Status from FDA for Oral Laquinimod Genzyme Signs an Agreement with Bayer Healthcare EMD Serono to Set Up Research Facility in Massachusetts EMD Serono Enters into a Partnership with Fast Forward Biogen Idec Secures US-FDA Approval for Production Process of TYSABRI Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated Interferon Beta-1a Bayer Schering Pharma Receives SFDA of China Approval for Betaferon Merck Serono Signs an Agreement with Bionomics Orasi Medical Establishes New Office in Tokyo Merck Serono and Ambrx to Extend Collaboration for Multiple Sclerosis Kineta Acquires Novel Therapeutic Compounds from Airmid MediciNova Enters into Agreement with Avigen Biogen Idec Takes Over Facet Biotech Teva Pharmaceutical Industries to Take over CoGenesys

4 Merck Serono Introduces RebiSmartTM Electronic Injection Device Bayer to Launch Betaferon Titration Pack MediciNova Announces Phase II Clinical Trial Results of The Myelin Repair Foundation Signs Strategic Deal with Dalton Pharma Services Acorda Therapeutics Takes Over Neurorecovery Bayer to Introduce 30-Gauge Needle for Betaferon Biogen Idec Commences Late-Stage Trial of Oral Compound Bayer Acquires Biologics Manufacturing Plant from Novartis 7. FOCUS ON SELECT PLAYERS Bayer Schering Pharma AG (Germany) Biogen Idec Inc. (US) Elan Pharmaceuticals, Inc. (US) Genzyme Corp. (US) Merck Serono SA (Switzerland) Novartis AG (Switzerland) Sanofi-Aventis SA (France) Teva Pharmaceuticals Industries Limited (Israel) 8. GLOBAL MARKET PERSPECTIVE Table 4: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region - US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 Table 5: World 10-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 Table 6: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Leading Drugs - Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 Table 7: World 10-year Perspective for Multiple Sclerosis Therapeutics by Leading Drugs - Percentage Breakdown of Dollar Sales for Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart) III. MARKET 1. THE UNITED STATES Table 8: US Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010

5 Strategic Corporate Developments Key Players Biogen Idec, Inc. Elan Pharmaceuticals, Inc. EMD Serono, Inc. Genzyme Corp. Table 9: US Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart) 2. JAPAN Table 10: Japanese Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010 Strategic Corporate Development Table 11: Japanese Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through EUROPE Table 12: Multiple Sclerosis Prevalence in Select European Countries for Years 2001 through 2010 (includes corresponding Graph/Chart) Low Penetration to Fuel Growth in European MS DMDs Market Oral Medication for MS in Near Future Strategic Corporate Development Key Players Bayer Schering Pharma AG (Germany) Merck Serono SA (Switzerland) Novartis AG (Switzerland) Sanofi-Aventis SA (France) Table 13: European Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through REST OF WORLD

6 Increasing Incidence of Multiple Sclerosis in Canada Strategic Corporate Developments Key Player Teva Pharmaceuticals Industries Limited (Israel) Table 14: Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 45 (including Divisions/Subsidiaries - 51) Region/Country Players The United States 26 Canada 3 Japan 1 Europe 18 France 1 Germany 4 The United Kingdom 3 Rest of Europe 10 Asia-Pacific (Excluding Japan) 2 Middle East 1

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013 Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

Multiple Sclerosis Drug Discoveries - What the Future Holds

Multiple Sclerosis Drug Discoveries - What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally

More information

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with

More information

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18)

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Scope of the Report The report titled Global Multiple Sclerosis Market: Trends & Opportunities (2013-18) provides an insight into the

More information

Multiple Sclerosis Treatments: World Market Outlook to 2011

Multiple Sclerosis Treatments: World Market Outlook to 2011 Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating

More information

Multiple Sclerosis. Global Drug Forecast and Market Analysis to 2022 Event-Driven Update. GDHC34PIDR / Published April 2013

Multiple Sclerosis. Global Drug Forecast and Market Analysis to 2022 Event-Driven Update. GDHC34PIDR / Published April 2013 Multiple Sclerosis Global Drug Forecast and Market Analysis to 2022 Event-Driven Update GDHC34PIDR / Published April 2013 Executive Summary The table below presents the key metrics for multiple sclerosis

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple Brochure More information from http://www.researchandmarkets.com/reports/2541548/ PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Description: PharmaPoint: Multiple

More information

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

Growth in revenue from MS drugs has been driven largely by price increases over the last several years. March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera

More information

Global Multiple Sclerosis Drugs Market 2014-2018

Global Multiple Sclerosis Drugs Market 2014-2018 Brochure More information from http://www.researchandmarkets.com/reports/2925806/ Global Multiple Sclerosis Drugs Market 2014-2018 Description: About Multiple Sclerosis and Disease Types Multiple sclerosis

More information

Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs

Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs Brochure More information from http://www.researchandmarkets.com/reports/706246/ Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs Description: Only about 36% of Multiple Sclerosis (MS)

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report

Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1382330/ Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report Description: This report analyzes the Global market

More information

What is Multiple Sclerosis? Gener al information

What is Multiple Sclerosis? Gener al information What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal

More information

Sales Force Automation (SFA) - Global Strategic Business Report

Sales Force Automation (SFA) - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1382310/ Sales Force Automation (SFA) - Global Strategic Business Report Description: This report analyzes the Global market for

More information

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective

More information

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective

More information

Moving Bed Bioreactor (MBBR) - Global Strategic Business Report

Moving Bed Bioreactor (MBBR) - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1824156/ Moving Bed Bioreactor (MBBR) - Global Strategic Business Report Description: This report analyzes the worldwide markets

More information

JULY-SEPTEMBER 2010. Image Copyright: REUTERS/Tim Wimborne Spotlight On... Multiple Sclerosis AWARDED TO THOMSON SCIENT FIC LIMITED

JULY-SEPTEMBER 2010. Image Copyright: REUTERS/Tim Wimborne Spotlight On... Multiple Sclerosis AWARDED TO THOMSON SCIENT FIC LIMITED AWARDED TO THOMSON SCIENT FIC LIMITED Image Copyright: REUTERS/Tim Wimborne Spotlight On... Multiple Sclerosis A PHARMA MATTERS report. JULY-SEPTEMBER 2010 Expert therapy area review of the key market

More information

Patient Group Input to CADTH

Patient Group Input to CADTH Patient Group Input to CADTH Section 1 General Information Name of the drug CADTH is reviewing and indication(s) of interest Name of patient group/author of submission Patient group s contact information:

More information

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International

More information

How to S.E.A.R.C.H. SM for the Right MS Therapy For You!

How to S.E.A.R.C.H. SM for the Right MS Therapy For You! How to S.E.A.R.C.H. SM for the Right MS Therapy For You! The Changing Landscape The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by the United States Food and Drug Administration

More information

MEDICAL POLICY STATEMENT

MEDICAL POLICY STATEMENT MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 10/01/2013 10/1/2015 08/25/2015 Policy Name Policy Number Multiple Sclerosis Therapy Class SRx-0022

More information

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster

More information

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011 Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,

More information

Enterprise Service Bus (ESB) - Global Strategic Business Report

Enterprise Service Bus (ESB) - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1227828/ Enterprise Service Bus (ESB) - Global Strategic Business Report Description: This report analyzes the Global market for

More information

Professional Service Automation (PSA) Software - Global Strategic Business Report

Professional Service Automation (PSA) Software - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1882060/ Professional Service Automation (PSA) Software - Global Strategic Business Report Description: This report analyzes the

More information

J.P. Morgan Cazenove Therapeutic Seminar

J.P. Morgan Cazenove Therapeutic Seminar Jannan, MS J.P. Morgan Cazenove Therapeutic Seminar David Meeker - CEO, Genzyme June 25, 2012 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private

More information

Medical Equipment Rental and Leasing - Global Strategic Business Report

Medical Equipment Rental and Leasing - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1824134/ Medical Equipment Rental and Leasing - Global Strategic Business Report Description: This report analyzes the worldwide

More information

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

Lemtrada (alemtuzumab)

Lemtrada (alemtuzumab) Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be

More information

A neurologist would assess your eligibility and suitability for the DMTs.

A neurologist would assess your eligibility and suitability for the DMTs. Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.

More information

National Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013

National Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013 National Multiple Sclerosis Society Disease Modification in Multiple Sclerosis Current as of January 2, 2013 Since 1993, the U.S. Food and Drug Administration (FDA) has approved several medications for

More information

The MS Disease- Modifying Drugs. Gener al information

The MS Disease- Modifying Drugs. Gener al information The MS Disease- Modifying Drugs Gener al information Current as of October 30, 2009. This online version is updated as breaking news requires. If you have downloaded and printed a copy from the web, please

More information

Study Support Materials Cover Sheet

Study Support Materials Cover Sheet Study Support Materials Cover Sheet Document Title ESCALATE Patient Brochure Intended Audience This brochure is designed to be given to potentially eligible patients as a take-home summary of key information

More information

Progress in MS: Current and Emerging Therapies

Progress in MS: Current and Emerging Therapies Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the

More information

Building on Leading Market Positions

Building on Leading Market Positions Building on Leading Market Positions Bharat Tewarie Head of Global Business Franchise Neurodegenerative Diseases Darmstadt, May 15, 2012 Agenda 1. Introduction 2. Rebif: Defending the franchise 3. Fertility:

More information

The MS Disease- Modifying Medications

The MS Disease- Modifying Medications The MS Disease- Modifying Medications National MS Society 1 Current as of November 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,

More information

Clinical Trial Management Systems (CTMS) - Global Strategic Business Report

Clinical Trial Management Systems (CTMS) - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1824112/ Clinical Trial Management Systems (CTMS) - Global Strategic Business Report Description: This report analyzes the worldwide

More information

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical

More information

Commercial Perspectives: Multiple Sclerosis

Commercial Perspectives: Multiple Sclerosis A Datamonitor Report Commercial Perspectives: Multiple Sclerosis How to Find Opportunities in an Unremitting Market Published: Jun-04 Product Code: Providing you with: In-depth profiles of current market-leading

More information

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

A blood sample will be collected annually for up to 2 years for JCV antibody testing. Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:

More information

Interferon beta products: risk of thrombotic microangiopathy and nephrotic syndrome

Interferon beta products: risk of thrombotic microangiopathy and nephrotic syndrome Monday 1 st September, 2014 Interferon beta products: risk of thrombotic microangiopathy and nephrotic syndrome Dear Healthcare Professional, The Medicines and Healthcare Products Regulatory Agency in

More information

Resources for the Patient. Please print these out and give them to your patients with MS

Resources for the Patient. Please print these out and give them to your patients with MS Resources for the Patient Please print these out and give them to your patients with MS An internet program for persons with MS on the FCM website Multiple Sclerosis: A Toolbox of Information and Resources

More information

The MS Disease- Modifying Medications GENERAL INFORMATION

The MS Disease- Modifying Medications GENERAL INFORMATION The MS Disease- Modifying Medications GENERAL INFORMATION Current as of March 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please

More information

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health

More information

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015 Brochure More information from http://www.researchandmarkets.com/reports/3293079/ Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015 Description: Relapsing Remitting Multiple Sclerosis

More information

Application Delivery Controllers (ADC) - Global Strategic Business Report

Application Delivery Controllers (ADC) - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/3301136/ Application Delivery Controllers (ADC) - Global Strategic Business Report Description: This report analyzes the worldwide

More information

Customer Experience Monitoring - Global Strategic Business Report

Customer Experience Monitoring - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/2666990/ Customer Experience Monitoring - Global Strategic Business Report Description: This report analyzes the worldwide markets

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Three years ago, the mantra for

Three years ago, the mantra for MANAGING MS: Trends, Issues, and Perspectives The entry of oral medications for multiple sclerosis into the marketplace and the high cost of biologic drugs are presenting new challenges for stakeholders.

More information

TABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.

TABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1. 1 Disclaimer The research reports provided by AM Mindpower Solutions are for the personal information of the authorised recipient and is not for public distribution and should not be reproduced or redistributed

More information

The MS Disease- Modifying Medications

The MS Disease- Modifying Medications The MS Disease- Modifying Medications National MS Society 1 Current as of January 2015. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,

More information

Progress in the field: therapeutic improvements for all patients?

Progress in the field: therapeutic improvements for all patients? Progress in the field: therapeutic improvements for all patients? Krzysztof Selmaj, Department of Neurology, Medical University of Lodz, PL Warsaw 15 May, 2015 Main features of MS Inflammation Demyelination

More information

Shale Gas - North America Strategic Business Report

Shale Gas - North America Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/3440912/ Shale Gas - North America Strategic Business Report Description: This report analyzes the North American market for Shale

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

How to S.E.A.R.C.H. for the Right MS Therapy for You!

How to S.E.A.R.C.H. for the Right MS Therapy for You! How to S.E.A.R.C.H. for the Right MS Therapy for You! How to S.E.A.R.C.H. for the Right MS Therapy for You! Copyright Multiple Sclerosis Association of America, 2012. All rights reserved. This booklet

More information

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Brochure More information from http://www.researchandmarkets.com/reports/2904677/ Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Pleural Mesothelioma - Pipeline Review,

More information

Resources for the Primary Care Provider. Please print these out for reference

Resources for the Primary Care Provider. Please print these out for reference Resources for the Primary Care Provider Please print these out for reference Resources for providers American Academy of Neurology www.aan.com Provides education and resources, such as guidelines for clinical

More information

Uncertainty in Benefit and Risk: Tysabri (natalizumab)

Uncertainty in Benefit and Risk: Tysabri (natalizumab) Uncertainty in Benefit and Risk: Tysabri (natalizumab) Robert J. Temple, M.D. Deputy Center Director for Clinical Science Center for Drug Evaluation and Research U.S. Food and Drug Administration IOM Drug

More information

Content Delivery Network (CDN): Market Research Report

Content Delivery Network (CDN): Market Research Report Content Delivery Network (CDN): Market Research Report Phone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com Content Delivery Network (CDN): Market Research Report Date: January 7,

More information

Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD

Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD Treatment in Relapsing MS: Choosing Among the Options Donald Negroski, MD Disclosures Research Grants Educational activities and lectures Consulting or other services including Continuing Medical Education

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

E1/T1 Transceivers (LIU/Framer) - Global Strategic Business Report

E1/T1 Transceivers (LIU/Framer) - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/2769232/ E1/T1 Transceivers (LIU/Framer) - Global Strategic Business Report Description: This report analyzes the worldwide markets

More information

Genzyme s Multiple Sclerosis Franchise Featured at AAN

Genzyme s Multiple Sclerosis Franchise Featured at AAN PRESS RELEASE Genzyme s Multiple Sclerosis Franchise Featured at AAN - Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs - Paris, France March 13, 2013 Sanofi (EURONEXT:

More information

Can an administrative drug claims database be used to understand claimant drug utilization?

Can an administrative drug claims database be used to understand claimant drug utilization? Can an administrative drug claims database be used to understand claimant drug utilization? By Elaine McKenzie, BSP, MBA, Consultant, TELUS Health Analytics Elaine McKenzie is a consultant who works with

More information

IMMUNOCHEMICALS - A Global Strategic Business Report

IMMUNOCHEMICALS - A Global Strategic Business Report /wepdwukltuyot IMMUNOCHEMICALS - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天 地 大 厦 A2 座 1008-1 室 (100080) 出 版 日 期 :April 2011

More information

Managed Mobility Services (MMS) - Global Strategic Analysis

Managed Mobility Services (MMS) - Global Strategic Analysis Brochure More information from http://www.researchandmarkets.com/reports/3619369/ Managed Mobility Services (MMS) - Global Strategic Analysis Description: This report analyzes the worldwide markets for

More information

EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston

EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Erin-Marie Beals Phone 1-781-681-2850 September 9, 2014 EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Data include

More information

Professional Service Automation (PSA) Software: Market Research Report

Professional Service Automation (PSA) Software: Market Research Report Professional Service Automation (PSA) Software: Market Research Report Phone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com Professional Service Automation (PSA) Software: Market Research

More information

ULC (Ultra Low Cost) Phones/Handsets - Global Strategic Business Report

ULC (Ultra Low Cost) Phones/Handsets - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1382320/ ULC (Ultra Low Cost) Phones/Handsets - Global Strategic Business Report Description: This report analyzes the Global market

More information

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone )

Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone ) Treatments for MS: Immunotherapy There are currently several disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity

More information

New treatments in MS What s here and what s nearly here

New treatments in MS What s here and what s nearly here 5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability

More information

DIY Industry - Global Outlook

DIY Industry - Global Outlook Brochure More information from http://www.researchandmarkets.com/reports/661677/ DIY Industry - Global Outlook Description: The global outlook series on the DIY Industry provides a collection of statistical

More information

Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice

Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice A Datamonitor report Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice Published: Dec-06 Product Code: Providing you with: An overview of epidemiology,

More information

Multiple Sclerosis Agents Step Therapy with Quantity Limit Program Summary

Multiple Sclerosis Agents Step Therapy with Quantity Limit Program Summary Multiple Sclerosis Agents Step Therapy with Quantity Limit Program Summary OBJECTIVE The intent of the Multiple Sclerosis (MS) Agents Step Therapy (ST) program is to encourage the use of preferred multiple

More information

Disease modifying drug therapy. what you need to know

Disease modifying drug therapy. what you need to know Disease modifying drug therapy what you need to know Contact information Neurologist s name: Neurologist s secretary: Telephone number: MS specialist nurse: Telephone number: Manufacturer helpline number:

More information

Ophthalmic Lasers - Global Outlook

Ophthalmic Lasers - Global Outlook Brochure More information from http://www.researchandmarkets.com/reports/1084174/ Ophthalmic Lasers - Global Outlook Description: The global outlook series on Ophthalmic Lasers provides a collection of

More information

If you have any questions about GLG Research Studies or you want to commission a Custom Report, please contact Sam Jacobs sjacobs@glgroup.com.

If you have any questions about GLG Research Studies or you want to commission a Custom Report, please contact Sam Jacobs sjacobs@glgroup.com. GLG Research Study Tysabri for Multiple Sclerosis Views from 245 Neurologists A GLG Research Study of 245 US-based neurologists about their opinion of Tysabri for the treatment of multiple sclerosis, given

More information

Enterprise Media Gateways - Global Strategic Business Report

Enterprise Media Gateways - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/3397954/ Enterprise Media Gateways - Global Strategic Business Report Description: This report analyzes the worldwide markets for

More information

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine

More information

Annual Report on Form 20-F

Annual Report on Form 20-F Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines

More information

Integrating New Treatments: A Case Based Approach

Integrating New Treatments: A Case Based Approach Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide

More information

Published by MSAA in February 2014

Published by MSAA in February 2014 Published by MSAA in February 2014 VITAMIN D MSAA s MS Research Update is published annually as a service to the MS community. This update provides an overview of the research behind the approved and experimental

More information

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based

More information

Personalised Medicine in MS

Personalised Medicine in MS Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective

More information

Multiple Sclerosis (MS) Class Update

Multiple Sclerosis (MS) Class Update Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Multiple Sclerosis (MS) Class Update Month/Year of

More information

The rising cost of prescription drugs to treat multiple sclerosis in upstate New York

The rising cost of prescription drugs to treat multiple sclerosis in upstate New York T H E F A C T S A B O U T The rising cost of prescription drugs to treat multiple sclerosis in upstate New York Per-person mean annual prescription drug cost to treat multiple sclerosis Annual drug cost

More information

Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of

Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of September 10, 2014 Contact: Shikha Virdi 905-919-0200 ext. 5504 EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston Data

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE May 11, 2015 SUBJECT EFFECTIVE DATE May 18, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Multiple Sclerosis Agents Pharmacy Service Leesa M. Allen, Deputy Secretary

More information

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies Brochure More information from http://www.researchandmarkets.com/reports/1504775/ Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

More information

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis May 25, 2015 Contact: Shikha Virdi 905-919-0200 ext. 5504 Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis Rebif now reimbursed under Ontario Drug Benefit Program

More information

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is

More information

b y G a r y S u l l i v a n

b y G a r y S u l l i v a n S p e c i a l R E S e a R C H i s s u e Happening Now Bulletins from clinical trials of new MS therapies b y G a r y S u l l i v a n A mere 20 years ago, physicians had little besides sympathy to offer

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information